drugset / Trial / NCT07746271
Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial
Phase 3
Not yet recruiting
4120 enrolled
The George Washington University Biostatistics Center
Brown University · collabEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabUniversity of Alabama at Birmingham · collabUniversity of Utah · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pressure (BP) of \<140/90 mmHg or to no treatment for non-severe hypertension \< 160/110 mmHg (usual care). The primary endpoint is an adverse pregnancy composite comprised of preeclampsia with end-organ damage, medically indicated preterm delivery \<37 weeks 0 days gestation, fetal/neonatal/infant death, or placental abruption.
Timeline
- Start
- 2026-09-30
- Primary completion
- 2029-12-31
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg | Unknown | — | — |
| Subject | Labetalol | Small molecule | — | — |